BioNTech (NASDAQ:BNTX) PT Raised to $150.00

BioNTech (NASDAQ:BNTX) had its price objective raised by Bank of America from $125.00 to $150.00 in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

BNTX has been the topic of several other reports. TD Cowen reduced their price objective on BioNTech from $98.00 to $85.00 and set a hold rating on the stock in a research report on Tuesday, August 6th. HSBC raised shares of BioNTech from a hold rating to a buy rating in a research report on Friday, August 2nd. Hsbc Global Res upgraded BioNTech from a hold rating to a strong-buy rating in a report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of BioNTech from a hold rating to a buy rating and set a $95.00 target price for the company in a report on Wednesday, August 7th. Finally, HC Wainwright reissued a buy rating and set a $113.00 price objective on shares of BioNTech in a research report on Monday. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $120.31.

BioNTech Trading Down 7.3 %

NASDAQ:BNTX opened at $115.62 on Monday. The firm’s fifty day moving average is $89.02 and its 200-day moving average is $90.14. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market cap of $27.49 billion, a P/E ratio of 231.24 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company’s revenue for the quarter was down 23.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.86) earnings per share. Equities analysts expect that BioNTech will post -2.8 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after acquiring an additional 150 shares during the period. Frazier Financial Advisors LLC purchased a new stake in shares of BioNTech during the fourth quarter worth about $30,000. Covestor Ltd lifted its stake in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares during the period. EverSource Wealth Advisors LLC boosted its position in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares during the last quarter. Finally, Crewe Advisors LLC acquired a new stake in shares of BioNTech during the first quarter worth $75,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.